Twist Bioscience (NASDAQ:TWST) Hits New 1-Year High – What’s Next?

Shares of Twist Bioscience Corporation (NASDAQ:TWST) hit a new 52-week high during trading on Wednesday . The company traded as high as $104.31 and last traded at $103.2480, with a volume of 339353 shares trading hands. The stock had previously closed at $102.88.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Leerink Partners set a $80.00 price objective on shares of Twist Bioscience in a report on Friday, May 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. TD Cowen lifted their price target on Twist Bioscience from $68.00 to $89.00 and gave the company a “buy” rating in a research note on Monday, June 15th. Piper Sandler assumed coverage on Twist Bioscience in a report on Thursday, June 11th. They set an “overweight” rating and a $85.00 price objective for the company. Finally, Guggenheim increased their price objective on Twist Bioscience from $60.00 to $107.00 and gave the stock a “buy” rating in a research note on Monday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and an average price target of $79.30.

Twist Bioscience Stock Performance

The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42. The company’s fifty day moving average price is $68.71 and its 200 day moving average price is $52.54. The company has a market cap of $6.47 billion, a PE ratio of -77.96 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The firm had revenue of $110.72 million for the quarter, compared to analysts’ expectations of $107.64 million. During the same quarter last year, the firm posted ($0.66) earnings per share. The firm’s revenue for the quarter was up 19.3% compared to the same quarter last year. On average, equities research analysts predict that Twist Bioscience Corporation will post -2.02 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 18,880 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $95.00, for a total value of $1,793,600.00. Following the transaction, the chief executive officer owned 824,039 shares in the company, valued at $78,283,705. The trade was a 2.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jan Johannessen sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total value of $673,440.00. Following the completion of the transaction, the director directly owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. This represents a 40.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 67,580 shares of company stock worth $5,169,482. 3.08% of the stock is owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently made changes to their positions in the business. Stifel Financial Corp raised its stake in shares of Twist Bioscience by 3.6% during the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after purchasing an additional 271 shares during the period. D.A. Davidson & CO. boosted its holdings in shares of Twist Bioscience by 1.2% in the 4th quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after buying an additional 305 shares during the last quarter. CWM LLC grew its position in Twist Bioscience by 9.4% during the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock valued at $150,000 after buying an additional 407 shares during the period. California State Teachers Retirement System increased its holdings in Twist Bioscience by 0.8% during the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after buying an additional 442 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in Twist Bioscience by 89.7% during the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after buying an additional 453 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.